FDA Approves Generic Long-Acting HIV Prevention Injection, $40 per Dose

The FDA approved a generic version of a twice-yearly HIV prevention injection, reducing infection risk by 99.9% and priced at $40, aiming to improve access in low-income countries. The approval, announced Monday, marks a significant step in expanding affordable HIV prophylaxis globally. The Indian manufacturer's generic entry could disrupt existing market dynamics, though supply and distribution details remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works